EGFR and small cell lung carcinoma: On the other hand, transformed SCLC typically arises as a resistance mechanism in EGFR-mutant or ALK-rearranged lung adenocarcinoma following tyrosine kinase inhibitor (TKI) therapy [114,115,116,117,118].